Stock listing
Samsung Biologics Co., Ltd.
Selected listing: 207940 · KRX · KRW · KR
Samsung Biologics Co., Ltd. (KRX:207940), Health Technology. Latest release Aug 31, 2026: Samsung Biologics publishes prospectus for PolyPeptide public tender…
- Ticker
- KRX:207940
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- KRX
- Currency
- KRW
About Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd. is a leading biopharmaceutical company based in Korea, specializing in contract manufacturing and development services for biologics. Samsung Biologics is recognized for its advanced manufacturing capabilities and commitment to quality in the biopharmaceutical industry.
Latest news from Samsung Biologics Co., Ltd.
Samsung Biologics publishes prospectus for PolyPeptide public tender offer
August 31, 2026
Samsung Biologics Reports Second Quarter 2026 Financial Results
July 22, 2026
Samsung Biologics announces all-cash offer to acquire PolyPeptide, accelerating multi-modality strategy and expanding global network across U.S., Europe, and India
July 19, 2026
Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
June 30, 2026
Samsung Biologics : 2025 FY Audited Financial Statements (Consolidated)
May 20, 2026
Research Samsung Biologics Co., Ltd.
Samsung Biologics Co., Ltd. company profile
View the public company page for Samsung Biologics Co., Ltd. on 6ix.
Samsung Biologics Co., Ltd. news
Read company news and market updates connected to Samsung Biologics Co., Ltd..
Samsung Biologics Co., Ltd. investor events
Find investor webinars, events, and replay context for Samsung Biologics Co., Ltd..